TLR9 and colorectal carcinoma: Consistent with these studies, we show here that the addition of a class A TLR9 agonist (ODN1585) enhanced the antitumor responses of anti–PD-1 therapy in peritoneal metastases derived from microsatellite-instable MC38 and microsatellite-stable CT26 colorectal carcinoma.